FDA Clears AI-Powered Software for Thyroid Ultrasound
Providing automated TI-RADS classifications and worksheets, the new AI-enabled software may facilitate improved efficiency with thyroid ultrasound exams.
The Food and Drug Administration (FDA) has granted 510(k) clearance for new AI-powered software geared toward thyroid ultrasound exams.
See-Mode Technologies, the developer of the software, said the software may help standardize assessment of thyroid ultrasound exams through automated TI-RADS classification of thyroid nodules. The company noted that results from a multi-reader, multi-case study demonstrated enhanced localization and characterization of thyroid nodules with adjunctive use of the AI software.
The newly FDA-cleared AI software from See-Mode Technologies for thyroid ultrasound exams reportedly provides automated TI-RADS classification of thyroid nodules. (Image courtesy of Adobe Stock.)
Facilitating workflow efficiency, the software also generates automated worksheets and reportedly streamlines reporting on follow-up thyroid studies, according to See-Mode Technologies.
“By bringing AI into routine clinical practice, we aim to reduce the reporting time and inter-operator variability that exists in thyroid ultrasound,” noted Milad Mohammadzadeh, a co-founder of See-Mode Technologies.
The company added that existing CPT codes for adjunctive AI interpretation of thyroid ultrasound may be applied for use of the See-Mode Technologies software.
Recent Videos
Related Content
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Article
Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025Article
The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025Article
The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
